Entry Point Capital, LLC Macrogenics Inc Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding MGNX
# of Institutions
130Shares Held
55.3MCall Options Held
87.3KPut Options Held
228K-
Bellevue Group Ag Kuesnacht, V89.93MShares$25.4 Million0.64% of portfolio
-
Armistice Capital, LLC New York, NY6.28MShares$16.1 Million0.29% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$13.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.32MShares$11.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.49MShares$8.93 Million0.06% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $157M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...